Oncogenic microRNA-155 and its target PU.1: an integrative gene expression study in six of the most prevalent lymphomas
Language English Country Japan Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
26261072
DOI
10.1007/s12185-015-1847-4
PII: 10.1007/s12185-015-1847-4
Knihovny.cz E-resources
- Keywords
- Lymphoma, PU.1, Prognosis, microRNA miR-155,
- MeSH
- ADP-ribosyl Cyclase 1 metabolism MeSH
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Lymphoma metabolism mortality MeSH
- MicroRNAs biosynthesis MeSH
- Biomarkers, Tumor biosynthesis MeSH
- Prevalence MeSH
- ZAP-70 Protein-Tyrosine Kinase metabolism MeSH
- Proto-Oncogene Proteins biosynthesis MeSH
- Gene Expression Regulation, Neoplastic * MeSH
- RNA, Neoplasm biosynthesis MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Trans-Activators biosynthesis MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- ADP-ribosyl Cyclase 1 MeSH
- MicroRNAs MeSH
- MIRN155 microRNA, human MeSH Browser
- Biomarkers, Tumor MeSH
- ZAP-70 Protein-Tyrosine Kinase MeSH
- proto-oncogene protein Spi-1 MeSH Browser
- Proto-Oncogene Proteins MeSH
- RNA, Neoplasm MeSH
- Trans-Activators MeSH
- ZAP70 protein, human MeSH Browser
The transcription factor PU.1 and its inhibitory microRNA-155 (miR-155) are important regulators of B-cell differentiation. PU.1 downregulation coupled with oncogenic miR-155 upregulation has been reported in lymphoid malignancies; however, these data have not been studied across different subtypes in relation to clinical outcomes. We studied expression of miR-155 and PU.1 in the six most prevalent human B-cell lymphomas (n = 131) including aggressive (DLBCL, HL, MCL) and indolent (B-CLL/SLL, MZL, FL) types. Levels of miR-155 and PU.1 inversely correlated in DLBCL, B-CLL/SLL, and FL tumor tissues. In HL tissues, an exceptionally high level of miR-155 was found in patients with unfavorable responses to first-line therapy and those who had shorter survival times. PU.1 downregulation was noted in B-CLL/SLL samples positive for the adverse prognostic markers CD38 and ZAP-70. Upregulation of miR-155 and downregulation of PU.1 expression are integral aspects of lymphoma biology that could mark aggressive behavior of some, but not all, lymphoma types.
See more in PubMed
Exp Hematol. 2007 Jul;35(7):1056-68 PubMed
Nature. 2010 Aug 12;466(7308):835-40 PubMed
Curr Opin Hematol. 2011 Jul;18(4):266-72 PubMed
Mol Cell Proteomics. 2012 May;11(5):77-89 PubMed
Blood. 2013 Sep 12;122(11):1891-9 PubMed
Immunity. 2007 Dec;27(6):847-59 PubMed
J Intern Med. 2008 Apr;263(4):366-75 PubMed
Blood. 2010 Apr 1;115(13):2630-9 PubMed
Proc Natl Acad Sci U S A. 2006 May 2;103(18):7024-9 PubMed
Blood. 2011 Mar 10;117(10):2827-38 PubMed
Cancer. 2007 Jun 15;109(12):2473-80 PubMed
Methods. 2001 Dec;25(4):402-8 PubMed
Blood. 2005 Sep 15;106(6):2083-90 PubMed
Immunity. 1998 Apr;8(4):509-16 PubMed
Blood. 2011 Apr 7;117(14):3816-25 PubMed
J Pathol. 2005 Oct;207(2):243-9 PubMed
Blood. 2013 Feb 7;121(6):962-70 PubMed
J Exp Med. 2014 Oct 20;211(11):2183-98 PubMed
Leukemia. 2005 May;19(5):750-8 PubMed
Blood Cells Mol Dis. 2003 Sep-Oct;31(2):229-33 PubMed
Proc Natl Acad Sci U S A. 2012 Jun 26;109(26):E1695-704 PubMed
J Pathol. 2006 Jul;209(3):352-9 PubMed
Int J Cancer. 2007 Sep 1;121(5):1156-61 PubMed
Neoplasia. 2009 Feb;11(2):167-76 PubMed
Haematologica. 2002 Oct;87(10):1021-7 PubMed
J Biol Chem. 1998 May 29;273(22):13375-8 PubMed
Leukemia. 2003 Dec;17(12):2426-34 PubMed
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3627-32 PubMed
